DGAP-News: WILEX AG: WILEX subsidiary Heidelberg Pharma signs license agreement for the development of Antibody Targeted

DGAP-News: WILEX AG: WILEX subsidiary Heidelberg Pharma signs license agreement 
for the development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche

DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: WILEX subsidiary Heidelberg Pharma signs license agreement
for the development of Antibody Targeted Amanitin Conjugates (ATACs)
with Roche

02.09.2013 / 07:02

---------------------------------------------------------------------

PRESS RELEASE 

WILEX subsidiary Heidelberg Pharma signs license agreement for the
development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche

Munich, Germany, 02 September 2013 - WILEX AG (ISIN DE0006614720 / WL6 /
FSE) today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg,
Germany, signed a license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY)
covering the development of a novel class of antibody drug conjugates
(ADCs) based on Heidelberg Pharma's patented technology to couple
α-Amanitin to antibodies. The license agreement covers initial joint
research to apply this technology to multiple Roche antibodies towards the
identification of development candidates with favourable efficacy/safety
profiles.

Heidelberg Pharma will receive regular payments for granting access to its
technology and providing research services. Roche will subsequently have
the opportunity to exercise options for licenses to develop and market
selected Antibody Targeted Amanitin Conjugates (ATACs). Heidelberg Pharma
will manufacture these substances and receive customary upfront payments,
milestone payments and royalties for each development candidate selected
by Roche.

α-Amanitin is a bicyclic peptide naturally occurring in the green Death Cap
mushroom. It potently inhibits the biosynthesis of RNA, a mechanism which
is critical for the survival of cells. Accordingly, ATACs exhibit
comparable activity against proliferating and resting tumour cells. This
proliferation independent activity differentiates ATACs from other ADCs,
which preferentially target proliferating tumour cells. As an additional
advantage ATACs could offer a substantial capability to overcome the
resistance mechanisms which might limit the efficacy of other antibody drug
conjugates. The ATACs tested so far have shown strong anti-tumour activity
in several preclinical tumour models.

Dr Jan Schmidt-Brand, Managing Director of Heidelberg Pharma GmbH and Chief
Financial Officer of WILEX AG, commented: 'We are delighted about the
opportunity to collaborate with a company as renowned as Roche. This
cooperation is an important external validation of our technology. We will
use this cooperation to jointly explore and technically expand the
applicability of our technology to selected antibodies.'

Dr Klaus Bosslet, heading Roche Discovery Oncology in Penzberg, Germany,
added: 'We look forward to collaborating with Heidelberg Pharma to elect
and develop the most promising ATACs. Ultimately, these ATACs may provide
novel treatment options for cancer patients, whose tumours do not respond
to available cancer therapeutics.'
 
About Heidelberg Pharma
Heidelberg Pharma GmbH is a wholly owned subsidiary of WILEX AG and is
located in Ladenburg, Germany. The Company offers services for the
pre-clinical drug discovery and development including explorative
pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and
molecular biology in oncology or inflammatory/autoimmune diseases. The
services are dedicated to a high grade of flexibility, efficient
realisation and high quality. Heidelberg Pharma's R&D flagship is its
proprietary 2nd generation ADC technology platform (ATAC) for more
effective anti-cancer drugs.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer. In the field of therapeutics, WILEX develops antibodies
and small molecules. (RENCAREX(R): Phase III, MESUPRON(R): Phase II,
WX-554: Phase Ib/II and WX-037: Phase I). In the field of diagnostics,
REDECTANE(R) is an antibody-based imaging agent that is currently in a
Phase III programme. The Company also has a portfolio of biomarker assays
that are marketed via its US subsidiary WILEX Inc. under the brand Oncogene
Science. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and a highly promising antibody drug conjugate
(ADC) technology platform. The business model of WILEX comprises research
and product development as well as the commercialisation of its activities.
WILEX's customers and partners include leading international pharmaceutical
companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 /
Symbol WL6.

Contact 

Corporate Communications & IR              Business Development
WILEX AG                                   Heidelberg Pharma GmbH
Katja Arnold (CIRO) & Sylvia Wimmer        Dr. Marcel Linssen
Grillparzerstr. 10                         CBO, Executive Vice President
81675 Munich, Germany                      Schriesheimer Str. 101
Tel.: +49 (0)89-41 31 38-126 / 29          68526 Ladenburg, Germany
Mobil: +49 (0)160 93 60 30 22              Tel.: +49-(0) 6203 1009-40
Email: investors[at]wilex.com              Email: m.linssen[at]hdpharma.com


This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward- looking statements to reflect future
events or developments.


End of Corporate News

---------------------------------------------------------------------

02.09.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     WILEX AG                                               
             Grillparzerstr. 10                                     
             81675 München                                          
             Germany                                                
Phone:       +49 (0)89 41 31 38 - 0                                 
Fax:         +49 (0)89 41 31 38 - 99                                
E-mail:      info@wilex.com                                         
Internet:    www.wilex.com                                          
ISIN:        DE0006614720                                           
WKN:         661472                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
228530 02.09.2013                                                      
 
Press spacebar to pause and continue. Press esc to stop.